Utilizing Niosome Nanoparticles for the Combined Treatment of Curcumin and Cisplatin in Oral Cancer

Authors

  • Fatemeh Rezaei Master of Pharmacy, Charles University, Faculty of Pharmacy, Hradec Kralove, Czech Republic.
  • Tara Fesharakinia Department of Biomedical Engineering, Faculty of Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
  • Soheil Balsini Gavanaroudi Department of Chemical Engineering, Youngstown State University, Ohio, USA.
  • Maryam Rezaeianjam MPH Candidate, Department of Public Health, University of Nevada, Las Vegas, Las Vegas, NV, USA.
  • Mahyar Khanlari Goodarzi College of Dentistry, University of East, Manila, Philippines.
  • Maasoume Abdollahi Department of Anatomical Sciences, Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran.
  • Kiomars Akaberi Departmant of Audiology, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Keywords:

Curcumin, Cisplatin, Niosome nanoparticles, Oral cancer, Drug release,

Abstract

Overview: Oral cancer remains a significant health challenge due to its aggressive nature and limited treatment options. This study investigates the use of niosome nanoparticles to deliver a combination of curcumin and cisplatin, a natural anti-inflammatory and anti-cancer agent and a widely used chemotherapeutic drug, respectively.

Methods: Niosome nanoparticles were formulated and optimized for encapsulation efficiency and stability. The physicochemical properties of the nanoparticles were characterized, including particle size, zeta potential, and polydispersity index (PDI). In vitro cytotoxicity assays were conducted using oral cancer cell lines to evaluate the efficacy of the combined treatment.

Results: The niosome formulations with a mean particle size of approximately 150 nm, a favorable zeta potential of 24.6 ± 3.2 mV, and a low PDI of 0.23 ± 0.05. The release profile showed a controlled and sustained release of both curcumin and cisplatin over 48 hours, with a cumulative release of 51% for curcumin and 48% for cisplatin. In vitro studies revealed that the combined treatment significantly reduced cell viability compared to individual treatments, with a synergistic effect observed at specific concentrations.

Conclusion: The findings suggest that niosome nanoparticles can effectively deliver a combination of curcumin and cisplatin, enhancing the therapeutic potential against oral cancer. This innovative approach may pave the way for more effective treatment strategies, ultimately improving patient outcomes in oral cancer therapy

Downloads

Published

2024-11-26

Issue

Vol. 9 No. 4 (2024)

Section

Research Articles/ Original Work

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).